Clinical Trial Update: Reactogenicity and Immunogenicity of Vaginal CNgp140 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the reactogenicity and immunogenicity of vaginal CNgp140 in HIV infection and AIDS; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immune Deficiency Syndrome
• HIV Infection

Drugs mentioned

• CNgp140 (gp140-based vaginal candidate)

Snippet

Sponsor: St George's, University of London | Conditions: HIV Infections, Acquired Immune Deficiency Syndrome | Phase 1 | Status: TERMINATED